Cetuximab + Tislelizumab + Chemotherapy in the Treatment of Unresectable LA HNSCC
Status:
RECRUITING
Trial end date:
2027-12-31
Target enrollment:
Participant gender:
Summary
This prospective, single-arm, Phase II study aims to evaluate the efficacy, safety, and surgical conversion rate of Cetuximab combined with Tislelizumab and chemotherapy for unresectable LA HNSCC.
Phase:
PHASE2
Details
Lead Sponsor:
Daping Hospital and the Research Institute of Surgery of the Third Military Medical University